These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 10412729)

  • 1. New insights into lipid metabolism in the nephrotic syndrome.
    Kaysen GA; de Sain-van der Velden MG
    Kidney Int Suppl; 1999 Jul; 71():S18-21. PubMed ID: 10412729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypoalbuminemia and proteinuria contribute separately to reduced lipoprotein catabolism in the nephrotic syndrome.
    Shearer GC; Stevenson FT; Atkinson DN; Jones H; Staprans I; Kaysen GA
    Kidney Int; 2001 Jan; 59(1):179-89. PubMed ID: 11135070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteinuria and plasma compositional changes contribute to defective lipoprotein catabolism in the nephrotic syndrome by separate mechanisms.
    Shearer GC; Kaysen GA
    Am J Kidney Dis; 2001 Jan; 37(1 Suppl 2):S119-22. PubMed ID: 11158876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences.
    Vaziri ND
    Kidney Int; 2016 Jul; 90(1):41-52. PubMed ID: 27165836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipoprotein metabolism in experimental nephrosis.
    Marsh JB
    Proc Soc Exp Biol Med; 1996 Nov; 213(2):178-86. PubMed ID: 8931662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased VLDL in nephrotic patients results from a decreased catabolism while increased LDL results from increased synthesis.
    de Sain-van der Velden MG; Kaysen GA; Barrett HA; Stellaard F; Gadellaa MM; Voorbij HA; Reijngoud DJ; Rabelink TJ
    Kidney Int; 1998 Apr; 53(4):994-1001. PubMed ID: 9551409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolism of apolipoprotein B-containing lipoproteins in subjects with nephrotic-range proteinuria.
    Warwick GL; Packard CJ; Demant T; Bedford DK; Boulton-Jones JM; Shepherd J
    Kidney Int; 1991 Jul; 40(1):129-38. PubMed ID: 1921148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-density lipoprotein metabolism and its association to plasma lipoprotein(a) in the nephrotic syndrome.
    Stenvinkel P; Berglund L; Ericsson S; Alvestrand A; Angelin B; Eriksson M
    Eur J Clin Invest; 1997 Feb; 27(2):169-77. PubMed ID: 9061312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Lipoproteins, apolipoproteins, lipoprotein lipase, hepatic triglyceride lipase and lecithin cholesterol acyltransferase in patients with nephrotic syndrome].
    Breier C; Lisch HJ; Drexel H; Braunsteiner H
    Schweiz Med Wochenschr; 1983 Jun; 113(25):909-13. PubMed ID: 6612272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pathologic decrease in lipoprotein lipase activity in relation to the development of hyperlipemias and their significance for coronary heart disease].
    Breier C
    Wien Klin Wochenschr Suppl; 1986; 167():1-16. PubMed ID: 3458343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipoprotein metabolism in nephrotic syndrome in childhood.
    Oetliker OH; Mordasini R; Lütschg J; Riesen W
    Pediatr Res; 1980 Jan; 14(1):64-6. PubMed ID: 7360522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ascites fluid lipoproteins in experimental nephrotic syndrome.
    Garber DW; Marsh JB
    Biochim Biophys Acta; 1988 Apr; 959(3):253-61. PubMed ID: 3355849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progression of renal failure: role of apolipoprotein B-containing lipoproteins.
    Attman PO; Samuelsson O; Alaupovic P
    Kidney Int Suppl; 1997 Dec; 63():S98-101. PubMed ID: 9407433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis and classification of dyslipidemia in renal disease.
    Attman PO; Samuelsson O; Alaupovic P
    Blood Purif; 1996; 14(1):49-57. PubMed ID: 8718566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of lipoprotein lipase and hepatic lipase on the transformation of VLDL and HDL during lipolysis of VLDL.
    Murdoch SJ; Breckenridge WC
    Atherosclerosis; 1995 Dec; 118(2):193-212. PubMed ID: 8770314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics of lipid metabolism under different urinary protein excretion in children with primary nephrotic syndrome.
    Hu P; Lu L; Hu B; Du PF
    Scand J Clin Lab Invest; 2009; 69(6):680-6. PubMed ID: 19468931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipolytic degradation of human very low density lipoproteins by human milk lipoprotein lipase: the identification of lipoprotein B as the main lipoprotein degradation product.
    Alaupovic P; Wang CS; McConathy WJ; Weiser D; Downs D
    Arch Biochem Biophys; 1986 Jan; 244(1):226-37. PubMed ID: 3080947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholesterol metabolism in glomerular cells: effect of lipoproteins from nephrotic patients.
    Wanner C; Krämer-Guth A; Nauck M; Quaschning T; Pavenstädt H; Schollmeyer P
    Miner Electrolyte Metab; 1996; 22(1-3):39-46. PubMed ID: 8676822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo.
    Ginsberg HN; Le NA; Goldberg IJ; Gibson JC; Rubinstein A; Wang-Iverson P; Norum R; Brown WV
    J Clin Invest; 1986 Nov; 78(5):1287-95. PubMed ID: 3095375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteinuria decreases tissue lipoprotein receptor levels resulting in altered lipoprotein structure and increasing lipid levels.
    Wang L; Shearer GC; Budamagunta MS; Voss JC; Molfino A; Kaysen GA
    Kidney Int; 2012 Nov; 82(9):990-9. PubMed ID: 22785171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.